BioSpace News Archive

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to release financial results for the third quarter 2020 before market open on Thursday, November 5, 2020.

The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at https://investor.regeneron.com/events-and-presentations.

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a Pre-IDE filing to the U.S. Food and Drug Administration and has requested a meeting with the FDA to discuss a few key matters in advance of the filing of its IDE application for the VenoValve U.S. pivotal trial.

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Systems (VLMS), today announced that a global biopharmaceutical company has selected ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system, to digitize its corporate validation process.

Eon, a Denver-based healthtech leader, announced that its data science models have been expanded to now also identify incidental pulmonary nodules on Magnetic Resonance (MR) and X-Ray radiology reports

Syntrix Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class product candidates focused on emerging immune control mechanisms in oncology indications, announced today it completed initial SX-682 dosing in Phase 1/2 trials in myelodysplastic syndromes (MDS) and metastatic melanoma.

ALERCELL, INC. (“ALERCELL”), a Biotechnology company specialized in delivering innovative in vitro rapid diagnostic tests, accurate and efficient, to tackle infectious diseases, today announced that Management will make a formal presentation at the Interactive MoneyShow Virtual Expo which will be held virtually on October 27 to

Central Oregon Radiology Assoc P.C. (CORA) has taken physician engagement to the next level by deploying RoyalMD® Provider Prime, the leader in referral management experience.

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has crossed the enrollment of 100 patients in its Phase 3 clinical trial ( Armada 2000) for patients with relapsed or refractory acute myeloid leukemia (AML). The multicenter, open-label, randomized pivotal trial is assessing the efficacy and safety of Rafael’s lead compound CPI-613® (devim

Genome & Company (KONEX: 314130), a global pioneer company of microbiome therapeutics, initiated clinical trials of GEN-001, an anti-cancer microbiome therapeutic (NCT04601402).